An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Inclusion Criteria:

* Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).
* Stable disease or better for at least 3 months on most recent treatment
* Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study
* Adequate blood testing, liver, and kidney function as required by the study.
* Eligible subjects will allow tissue samples to be examined and stored.

Exclusion Criteria:

* Patient has been treated with other investigational agents with a similar anti-tumor mechanism.
* Patient should not have failed more than 3 prior treatment regimens.